Disc Medicine (NASDAQ:IRON) Director Kevin Bitterman Sells 5,312 Shares of Company Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Kevin Bitterman sold 5,312 shares of Disc Medicine stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $79.95, for a total transaction of $424,694.40. Following the sale, the director directly owned 13,257 shares of the company’s stock, valued at $1,059,897.15. The trade was a 28.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Bitterman also recently made the following trade(s):

• On Wednesday, October 21st, Kevin Bitterman sold 25,519 shares of Disc Medicine stock. The shares were sold at an average price of $80.23, for a total transaction of $2,047,389.37.
• On Monday, October 19th, Kevin Bitterman sold 10,994 shares of Disc Medicine stock. The shares were sold at an average price of $79.97, for a total transaction of $879,190.18.
• On Friday, September 11th, Kevin Bitterman sold 27,136 shares of Disc Medicine stock. The shares were sold at an average price of $70.11, for a total transaction of $1,902,504.96.
• On Friday, September 4th, Kevin Bitterman sold 1,689 shares of Disc Medicine stock. The shares were sold at an average price of $79.96, for a total transaction of $135,052.44.
• On Thursday, September 3rd, Kevin Bitterman sold 5,203 shares of Disc Medicine stock. The stock was sold at an average price of $79.98, for a total transaction of $416,135.94.
• On Wednesday, September 2nd, Kevin Bitterman sold 49,164 shares of Disc Medicine stock. The stock was sold at an average price of $80.17, for a total value of $3,941,477.88.
• On Tuesday, September 1st, Kevin Bitterman sold 129 shares of Disc Medicine stock. The stock was sold at an average price of $79.95, for a total value of $10,313.55.

Disc Medicine Price Performance

Disc Medicine stock opened at $76.00 on Thursday. Disc Medicine, Inc. has a 12 month low of $40.00 and a 12 month high of $99.50. The stock’s 50 day moving average is $71.44 and its 200-day moving average is $71.47. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of -11.55 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.71) by $0.17. Equities research analysts expect that Disc Medicine, Inc. will post -6.61 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IRON. Morgan Stanley upped their price target on shares of Disc Medicine from $90.00 to $92.00 and gave the company an “overweight” rating in a research note on Tuesday. Wells Fargo & Company raised their price target on shares of Disc Medicine from $86.00 to $124.00 and gave the stock an “overweight” rating in a research report on Tuesday. Wall Street Zen cut shares of Disc Medicine from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. HC Wainwright reissued a “buy” rating and issued a $120.00 price objective on shares of Disc Medicine in a report on Thursday, September 10th. Finally, Wedbush increased their target price on shares of Disc Medicine from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $122.70.

Hedge Funds Weigh In On Disc Medicine

A number of hedge funds have recently added to or reduced their stakes in IRON. State of Wyoming bought a new position in Disc Medicine during the 2nd quarter worth $25,000. Allworth Financial LP bought a new stake in shares of Disc Medicine during the 2nd quarter valued at $46,000. Nykredit A S bought a new stake in shares of Disc Medicine during the 2nd quarter valued at $103,000. Quantbot Technologies LP acquired a new stake in shares of Disc Medicine during the 2nd quarter worth $153,000. Finally, Seven Fleet Capital Management LP acquired a new stake in shares of Disc Medicine during the 1st quarter worth $207,000. Institutional investors own 83.70% of the company’s stock.

Key Disc Medicine News

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Analyst price targets increased: Jefferies raised its price target to $149, while Cantor Fitzgerald lifted its target to $170 following positive Phase 3 results for bitopertin. The upgrades reinforce optimism about the drug’s potential in erythropoietic protoporphyria and related conditions. Jefferies raises Disc Medicine price target Cantor Fitzgerald raises Disc Medicine price target
• Positive Sentiment: $450 million financing strengthens the balance sheet: Disc Medicine priced an upsized offering of 6 million shares at $75 per share, with a possible 900,000-share overallotment. Proceeds will fund clinical development, research, and potential commercialization of bitopertin, potentially reducing financing risk and extending the company’s operating runway. Disc Medicine announces $450 million offering
• Neutral Sentiment: Unusually high options activity indicates elevated trading interest and expectations for volatility, but the report does not establish a clear directional signal. Disc Medicine sees unusually high options volume
• Negative Sentiment: Share dilution is weighing on the stock: The sale of 6 million new shares—following the previously announced $350 million offering—can reduce existing shareholders’ ownership percentage and create selling pressure around the $75 offering price.
• Negative Sentiment: Director selling adds an overhang: Director Kevin Bitterman sold a combined 41,825 shares for approximately $3.35 million across October 19–21, materially reducing his direct holdings. The transactions were conducted under a pre-arranged Rule 10b5-1 plan, which makes them less informative about current management expectations but still represents potential supply. Disc Medicine insider transaction filing

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.